NL192564C
(en)
*
|
1982-10-08 |
1997-10-03 |
Glaxo Group Ltd |
Device for administering medicaments to patients.
|
JPS63143081A
(en)
*
|
1986-12-05 |
1988-06-15 |
メクト株式会社 |
Inhalator
|
GB9021433D0
(en)
*
|
1990-10-02 |
1990-11-14 |
Atomic Energy Authority Uk |
Power inhaler
|
GB2253200A
(en)
*
|
1991-02-01 |
1992-09-02 |
Harris Pharma Ltd |
Inhalation apparatus and fracturable capsule for use therewith
|
GB9216038D0
(en)
*
|
1992-07-28 |
1992-09-09 |
Bespak Plc |
Dispensing apparatus for powdered medicaments
|
DE4318455A1
(en)
*
|
1993-06-03 |
1994-12-08 |
Boehringer Ingelheim Kg |
Capsule holder
|
DE19835346A1
(en)
*
|
1998-08-05 |
2000-02-10 |
Boehringer Ingelheim Pharma |
Two-part capsule for pharmaceutical preparations for powder inhalers
|
US6759398B2
(en)
|
2000-08-05 |
2004-07-06 |
Smithkline Beecham Corporation |
Anti-inflammatory androstane derivative
|
AU2001276497B2
(en)
|
2000-08-05 |
2005-04-07 |
Glaxo Group Limited |
17.beta.-carbothioate 17.alpha.-arylcarbonyloxyloxy androstane derivative as anti-inflammatory agents
|
GB0103630D0
(en)
|
2001-02-14 |
2001-03-28 |
Glaxo Group Ltd |
Chemical compounds
|
DE60101451T2
(en)
|
2001-03-05 |
2004-10-21 |
Pera Ivo E |
Inhaler for distributing powdered medication in a capsule through the respiratory tract
|
JP4143413B2
(en)
|
2001-03-22 |
2008-09-03 |
グラクソ グループ リミテッド |
Formanilide derivatives as β2-adrenergic receptor agonists
|
KR100831534B1
(en)
|
2001-04-30 |
2008-05-22 |
글락소 그룹 리미티드 |
Anti-inflammatory 17.beta.-carbothioate ester derivatives of androstane with a cyclic ester group in position 17.alpha
|
US7361787B2
(en)
|
2001-09-14 |
2008-04-22 |
Glaxo Group Limited |
Phenethanolamine derivatives for treatment of respiratory diseases
|
EP1487417A4
(en)
|
2001-09-17 |
2010-03-17 |
Glaxo Group Ltd |
Dry powder medicament formulations
|
JP2005523920A
(en)
|
2002-04-25 |
2005-08-11 |
グラクソ グループ リミテッド |
Phenetanolamine derivative
|
GB0217225D0
(en)
|
2002-07-25 |
2002-09-04 |
Glaxo Group Ltd |
Medicinal compounds
|
DE60320007T2
(en)
|
2002-10-28 |
2009-06-18 |
Glaxo Group Ltd., Greenford |
Phenthanolamine derivatives for the treatment of respiratory diseases
|
GB0303396D0
(en)
|
2003-02-14 |
2003-03-19 |
Glaxo Group Ltd |
Medicinal compounds
|
TW200519108A
(en)
|
2003-07-17 |
2005-06-16 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
MY143366A
(en)
|
2003-10-14 |
2011-04-29 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
MXPA06004242A
(en)
|
2003-10-17 |
2006-06-28 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists field of the invention.
|
TW200524577A
(en)
|
2003-11-04 |
2005-08-01 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
DE10352277A1
(en)
|
2003-11-08 |
2005-06-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
powder inhaler
|
GB0329182D0
(en)
|
2003-12-17 |
2004-01-21 |
Glaxo Group Ltd |
Chemical compounds
|
EP1725564A4
(en)
|
2004-03-17 |
2007-09-12 |
Glaxo Group Ltd |
M3 muscarinic acetylcholine receptor antagonists
|
AU2005227733A1
(en)
|
2004-04-02 |
2005-10-13 |
Glaxo Group Limited |
Chemical process and new crystalline form
|
MY144753A
(en)
|
2004-04-27 |
2011-10-31 |
Glaxo Group Ltd |
Muscarinic acetylcholine receptor antagonists
|
WO2005112644A2
(en)
|
2004-05-13 |
2005-12-01 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
US7556035B2
(en)
|
2004-05-28 |
2009-07-07 |
Quadrant Technologies Limited |
Unit dose dry powder inhaler
|
DE102005001332A1
(en)
|
2005-01-11 |
2006-07-20 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Two-piece capsule with pre-closure for holding pharmaceutical preparations for powder inhalers
|
JP5156397B2
(en)
|
2005-02-10 |
2013-03-06 |
グラクソ グループ リミテッド |
Method for producing lactose using preclassification technology and pharmaceutical preparation formed from the lactose
|
MY145281A
(en)
|
2005-03-25 |
2012-01-13 |
Glaxo Group Ltd |
Novel compounds
|
TW200724142A
(en)
|
2005-03-25 |
2007-07-01 |
Glaxo Group Ltd |
Novel compounds
|
WO2007022351A2
(en)
|
2005-08-18 |
2007-02-22 |
Glaxo Group Limited |
Muscarinic acetylcholine receptor antagonists
|
PT103481B
(en)
|
2006-05-16 |
2008-08-01 |
Hovione Farmaciencia S A |
INHALER OF SIMPLE USE AND INHALATION METHOD
|
AR065804A1
(en)
|
2007-03-23 |
2009-07-01 |
Smithkline Beecham Corp |
COMPOSITE OF INDOL CARBOXAMIDE, PHARMACEUTICAL COMPOSITION THAT UNDERSTANDS IT AND USE OF THIS COMPOUND TO PREPARE A MEDICINAL PRODUCT
|
GB2463451A
(en)
|
2008-09-08 |
2010-03-17 |
Cambridge Lab |
3, 11b cis-dihydrotetrabenazine compounds for use in the treatment of dementia
|
EP2400950B1
(en)
|
2009-02-26 |
2019-05-22 |
Glaxo Group Limited |
Pharmaceutical formulations comprising 4-{(1 r)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol
|
WO2010147947A2
(en)
|
2009-06-16 |
2010-12-23 |
Schering Corporation |
NOVEL [3,2-c] HETEROARYL STEROIDS AS GLUCOCORTICOID RECEPTOR AGONISTS, COMPOSITIONS AND USES THEREOF
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
ES2546422T5
(en)
|
2010-08-31 |
2023-01-20 |
Glaxosmithkline Ip Dev Ltd |
Dry powder inhalation medicinal products having moisture control properties and methods of administration thereof
|
ES2705494T3
(en)
|
2010-08-31 |
2019-03-25 |
Glaxosmithkline Ip Dev Ltd |
Pharmacological products for the inhalation of dry powder that have humidity control properties and methods of administration thereof
|
US9297813B2
(en)
|
2010-11-11 |
2016-03-29 |
Agency For Science, Technology And Research |
Targeting metabolic enzymes in human cancer
|
GB201116641D0
(en)
|
2011-09-27 |
2011-11-09 |
Glaxo Group Ltd |
Novel compounds
|
AR090847A1
(en)
|
2012-04-27 |
2014-12-10 |
Glaxo Group Ltd |
MODULATING COMPOUNDS OF THE ORPHAN RETINOID RECEIVER (ROR)
|
GB201207406D0
(en)
|
2012-04-27 |
2012-06-13 |
Glaxo Group Ltd |
Novel compounds
|
CA2891348C
(en)
|
2012-11-28 |
2020-04-28 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
CN107428828A
(en)
|
2015-03-11 |
2017-12-01 |
葛兰素史密斯克莱知识产权发展有限公司 |
TSLP associated proteins
|
ES2910938T3
(en)
|
2015-06-15 |
2022-05-17 |
Glaxosmithkline Ip Dev Ltd |
NRF2 regulators
|
AU2016280235A1
(en)
|
2015-06-15 |
2017-12-14 |
Astex Therapeutics Limited |
Nrf2 regulators
|
EA035864B1
(en)
|
2015-06-15 |
2020-08-21 |
Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Nrf2 regulators
|
UY36851A
(en)
|
2015-08-16 |
2017-03-31 |
Glaxosmithkline Ip Dev Ltd |
COMPOUNDS FOR USE IN ANTIBACTERIAL APPLICATIONS
|
JP2018529744A
(en)
|
2015-10-06 |
2018-10-11 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
Arylcyclohexylpyrazoles as NRF2 regulators
|
WO2017060854A1
(en)
|
2015-10-06 |
2017-04-13 |
Glaxosmithkline Intellectual Property Development Limited |
Biaryl pyrazoles as nrf2 regulators
|
US11260049B2
(en)
|
2016-09-20 |
2022-03-01 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
TRPV4 antagonists
|
WO2018055527A1
(en)
|
2016-09-20 |
2018-03-29 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Trpv4 antagonists
|
TW201825458A
(en)
|
2016-09-20 |
2018-07-16 |
英商葛蘭素史克智慧財產(第二)有限公司 |
TRPV 4 antagonists
|
KR20190088404A
(en)
|
2016-12-06 |
2019-07-26 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
3- (2,3-dihydro-1H-inden-5-yl) propanoic acid derivatives and their use as NRF2 regulators
|
EP3551620A1
(en)
|
2016-12-12 |
2019-10-16 |
GlaxoSmithKline Intellectual Property Development Limited |
3-carboxylic acid pyrroles as nrf2 regulators
|
EP3551621A1
(en)
|
2016-12-12 |
2019-10-16 |
GlaxoSmithKline Intellectual Property Development Limited |
N-aryl pyrazoles as nrf2 regulators
|
EP3555088B1
(en)
|
2016-12-14 |
2021-11-24 |
GlaxoSmithKline Intellectual Property Development Limited |
Bisaryl amides as nrf2 regulators
|
EP3555068B1
(en)
|
2016-12-14 |
2020-12-02 |
GlaxoSmithKline Intellectual Property Development Limited |
3-oxo-1,4-diazepinyle compounds as nrf2 activators
|
WO2018109643A1
(en)
|
2016-12-14 |
2018-06-21 |
Glaxosmithkline Intellectual Property Development Limited |
Bisaryl heterocycles as nrf2 acti
|
US11059816B2
(en)
|
2016-12-15 |
2021-07-13 |
Glaxosmithkline Intellectual Property Development Limited |
Ether linked triazoles as NRF2 activators
|
JP7110197B2
(en)
|
2016-12-15 |
2022-08-01 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド |
NRF2 activator
|
CA3059449A1
(en)
|
2017-04-24 |
2018-11-01 |
Cocrystal Pharma, Inc. |
Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication
|
WO2019116231A1
(en)
|
2017-12-11 |
2019-06-20 |
Glaxosmithkline Intellectual Property Development Limited |
Nrf2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ dysfunction syndrome
|
JP2021505636A
(en)
|
2017-12-11 |
2021-02-18 |
グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited |
NRF2 activator for the treatment of acute lung injury, acute respiratory distress syndrome and multiple organ failure syndrome
|
GB201720989D0
(en)
|
2017-12-15 |
2018-01-31 |
Glaxosmithkline Ip Dev Ltd |
Chemical compounds
|
TWI795510B
(en)
|
2018-01-17 |
2023-03-11 |
英商葛蘭素史密斯克藍智慧財產發展有限公司 |
PI4KIIIβ INHIBITORS
|
EP3796906A1
(en)
|
2018-05-23 |
2021-03-31 |
GlaxoSmithKline Intellectual Property Management Limited |
Indanes as nrf2 activators
|
EP3829719A1
(en)
|
2018-07-27 |
2021-06-09 |
Cocrystal Pharma, Inc. |
Pyrrolo[2,3-b]pyridin derivatives as inhibitors of influenza virus replication
|
EP3849978B1
(en)
|
2018-09-10 |
2022-11-02 |
Cocrystal Pharma, Inc. |
Pyridopyrazine and pyridotriazine inhibitors of influenza virus replication
|
AU2019361038A1
(en)
|
2018-10-17 |
2021-05-13 |
Cocrystal Pharma, Inc. |
Combinations of inhibitors of influenza virus replication
|
EA202191327A1
(en)
|
2018-11-13 |
2021-08-09 |
Кокристал Фарма, Инк. |
DOSAGE FORMS OF THERAPEUTIC PREPARATIONS FOR INFLUENZA
|
US20220048897A1
(en)
|
2018-11-26 |
2022-02-17 |
Cocrystal Pharma, Inc. |
Inhibitors of influenza virus replication
|
GB201908536D0
(en)
|
2019-06-13 |
2019-07-31 |
Glaxosmithkline Ip Dev Ltd |
Compounds
|
US20230151034A1
(en)
|
2020-03-17 |
2023-05-18 |
Cocrystal Pharma, Inc. |
Peptidomimetic n5-methyl-n2-(nonanoyl-l-leucyl)-l-glutaminate derivatives, triazaspiro[4.14]nonadecane derivatives and similar compounds as inhibitors of norovirus and coronavirus replication
|
IL297069A
(en)
|
2020-04-10 |
2022-12-01 |
Cocrystal Pharma Inc |
Inhibitors of norovirus and coronavirus replication
|
EP4138884A1
(en)
|
2020-04-20 |
2023-03-01 |
Sorrento Therapeutics, Inc. |
Pulmonary administration of ace2 polypeptides
|
WO2022175425A1
(en)
|
2021-02-22 |
2022-08-25 |
Glaxosmithkline Intellectual Property Development Limited |
Inhaled mtor kinase inhibitors for use in the treatment or the prevention of a respiratory rna virus infection
|
WO2022179967A1
(en)
|
2021-02-23 |
2022-09-01 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Vadadustat for treating covid-19 in a hospitalized subject
|
WO2023014758A1
(en)
|
2021-08-03 |
2023-02-09 |
Cocrystal Pharma, Inc. |
Inhibitors for coronaviruses
|